search

Active clinical trials for "Hyperlipoproteinemia Type II"

Results 51-60 of 215

Pediatric Reporting of Adult-Onset Genomic Results

Hereditary Breast and Ovarian Cancer SyndromeLynch Syndrome1 more

The Investigators will conduct a longitudinal, mixed-methods cohort study to assess primary and secondary psychosocial outcomes among 705 MyCode pediatric participants and their parents, and health behaviors of parents whose children receive an adult- or pediatric-onset genomic result. Data will be gathered via quantitative surveys using validated measures of distress, family functioning, quality of life, body image, perceived cancer/heart disease risk, genetic counseling satisfaction, genomics knowledge, and adjustment to genetic information; qualitative interviews with adolescents and parents; and electronic health records review of parents' cascade testing uptake and initiation of risk reduction behaviors. The investigators will also conduct empirical and theoretical legal research to examine the loss of chance doctrine and its applicability to genomic research.

Active4 enrollment criteria

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

Homozygous Familial Hypercholesterolemia (HoFH)

This long-term observational study is designed to follow subjects who, during another Clinical Study, received gene therapy treatment used to treat their Homozygous Familial Hypercholesterolemia (HoFH) disease. This study is intended to follow those subjects for up to 5 years since they received treatment to look for any long-term safety concerns. There is no investigational drug or therapy provided as part of this study.

Active2 enrollment criteria

Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent...

Familial Hypercholesterolemia

The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Terminated21 enrollment criteria

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol...

Hypercholesterolemia

The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), to lower cholesterol in subjects with homozygous familial hypercholesterolemia undergoing lipid-lowering treatment.

Terminated20 enrollment criteria

Long Term Safety Study of PRALUENT

Heterozygous Familial HypercholesterolemiaNon-familial Hypercholesterolemia

The primary objective of the study was to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed the neurocognitive function study R727-CL-1532 (NCT02957682). The secondary objectives of the study were: To evaluate the effect of PRALUENT on low-density lipoprotein cholesterol (LDL-C) To evaluate the effect of PRALUENT on other lipid parameters To evaluate the effect of PRALUENT on gonadal steroid hormones

Terminated9 enrollment criteria

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants...

Hyperlipoproteinemia Type IIHomozygous Familial Hypercholesterolemia

This study will evaluate the safety and effect of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) when added to ongoing lipid-lowering therapy. The primary hypothesis is that treatment with anacetrapib 100 mg for 12 weeks will lower LDL-C to a greater extent than treatment with placebo.

Terminated18 enrollment criteria

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid...

AtherosclerosisHeterozygous Familial Hypercholesterolemia

The effects of pactimibe versus placebo on the progression of atherosclerosis in the carotid arteries will be assessed using standard ultrasound techniques.

Terminated7 enrollment criteria

Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care

Heterozygous Familial Hypercholesterolaemia

Eprotirome is a liver selective thyroid hormone that can reduce several independent risk factors for cardiovascular disease, while an euthyroid state is preserved in the extrahepatic tissue. The purpose of this Phase III study is to assess the long-term efficacy and safety of Eprotirome in Patients with heterozygous Familial Hypercholesterolaemia who are on optimal standard of care.

Terminated5 enrollment criteria

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia (HoFH)

This first-in-human study is intended to evaluate the safety and preliminary effectiveness of AAV (Adeno-associated virus)-based liver-directed gene therapy in the treatment of adults with Homozygous Familial Hypercholesterolemia (HoFH).

Terminated11 enrollment criteria

School-based Education and Screening Program With Lipid Screening as a Means to Identify Familial...

Familial Hyperlipidemia

Determination of FH status by genetic testing in school age children who have demonstrated elevated cholesterol on baseline screening.

Enrolling by invitation2 enrollment criteria
1...567...22

Need Help? Contact our team!


We'll reach out to this number within 24 hrs